Literature DB >> 10994729

Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification.

R A Valdés-Olmos1, L Jansen, C A Hoefnagel, O E Nieweg, S H Muller, E J Rutgers, B B Kroon.   

Abstract

UNLABELLED: The aim of this study was to evaluate the findings of mammary lymphoscintigraphy by a single intratumoral injection in 150 patients with breast carcinoma: 100 patients (group A) investigated in the validation phase of the study and 50 (group B) studied after the tracer dose was optimized.
METHODS: Immediately after injection of 99mTc-nanocolloid using a 25-gauge needle and a 0.2-mL volume, simultaneous anterior and lateral images were acquired with a dual-head gamma camera during 20 min followed by sequential static anterior and prone lateral breast images after 30 min and after 2 and 4 h. 57Co-assisted skin marking defined the sentinel node location for subsequent gamma probe, blue dye-guided sentinel node biopsy.
RESULTS: In group A (mean dose, 61.6 MBq; range, 42-88 MBq) scintigraphy revealed lymph nodes in 83 patients (83%), with an increase in the rate of visualization from 72% for the first 40 patients to 90% for the last 60; patient age (P = 0.01) and administered tracer dose (P = 0.04) were found to be significant factors for visualization, with optimal results obtained from doses higher than 65 MBq. Lymph nodes were visible in 34 patients (41%) during the first 30 min after injection, whereas in 49 patients appearance occurred at 2-4 h. A total of 97 lymphatic basins were visualized (80 axillary, 3 clavicular, 14 internal mammary). In group B (mean dose, 90.8 MBq; range, 68-124 MBq), the visualization rate was 94%, with early lymph node appearance in 27 patients (57%) and a total of 53 basins (45 axillary, 8 internal mammary). In combination with intraoperative blue dye mapping and y probing, the identification rate increased to 90% in group A and 98% in group B. Prone lateral images contributed to identification of intramammary lymph nodes in a total of 14 patients and axillary nodes close to the injection site in 8 other patients.
CONCLUSION: Mammary lymphoscintigraphy by single intratumoral injection is a valid method for lymphatic mapping and identification of both axillary and nonaxillary sentinel nodes. Lymph node visualization appears to be improved with higher tracer doses. The compactness of the injection site enables high-quality additional lateral images that can depict intramammary or axillary lymph nodes adjacent to the injection site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10994729

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer.

Authors:  Iris M C van der Ploeg; Omgo E Nieweg; Bin B R Kroon; Emiel J T Rutgers; Marie-Jeanne T F D Baas-Vrancken Peeters; Wouter V Vogel; Cornelis A Hoefnagel; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-13       Impact factor: 9.236

2.  Results of preoperative lymphoscintigraphy for breast cancer are predictive of identification of axillary sentinel lymph nodes.

Authors:  Frédéric Marchal; Philippe Rauch; Olivier Morel; Jean Claude Mayer; Pierre Olivier; Agnès Leroux; Jean Luc Verhaeghe; François Guillemin
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

3.  Response to comment by Aprile et al.: the EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  F Giammarile; N Alazraki; J N Aarsvold; R A Audisio; E Glass; S F Grant; J Kunikowska; M Leidenius; V M Moncayo; R F Uren; W J Oyen; R A Valdés Olmos; S Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-26       Impact factor: 9.236

4.  Factors of importance for scintigraphic non-visualisation of sentinel nodes in breast cancer.

Authors:  A H Chakera; E Friis; U Hesse; N Al-Suliman; B Zerahn; B Hesse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-05       Impact factor: 9.236

5.  Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients.

Authors:  A Sanjuàn; S Vidal-Sicart; G Zanón; J Pahisa; M Velasco; P L Fernández; G Santamaría; B Farrús; M Muñoz; J Albanell; F Pons; J A Vanrell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-25       Impact factor: 9.236

6.  Feasibility of sentinel node detection in renal cell carcinoma: a pilot study.

Authors:  Axel Bex; Lenka Vermeeren; Geraldine de Windt; Warner Prevoo; Simon Horenblas; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-29       Impact factor: 9.236

7.  Lymphoscintigraphy and SPECT/CT in multicentric and multifocal breast cancer: does each tumour have a separate drainage pattern? Results of a Dutch multicentre study (MULTISENT).

Authors:  O R Brouwer; L Vermeeren; I M C van der Ploeg; R A Valdés Olmos; C E Loo; L M Pereira-Bouda; F Smit; P Neijenhuis; B C Vrouenraets; F Sivro-Prndelj; S M Jap-a-Joe; P J Borgstein; E J Th Rutgers; H S A Oldenburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-24       Impact factor: 9.236

8.  The hidden sentinel node and SPECT/CT in breast cancer patients.

Authors:  Iris M C van der Ploeg; Renato A Valdés Olmos; Bin B R Kroon; Emiel J T Rutgers; Omgo E Nieweg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-20       Impact factor: 9.236

9.  Sentinel lymphnode biopsy in early breast cancer using methylene blue dye and radioactive sulphur colloid - a single institution Indian experience.

Authors:  S P Somashekhar; S Zaveri Shabber; K Udupa Venkatesh; K Venkatachala; M M Vasan Thirumalai
Journal:  Indian J Surg       Date:  2008-07-24       Impact factor: 0.656

10.  Comparison of a 1-day and a 2-day protocol for lymphatic mapping and sentinel lymph node biopsy in patients with nonpalpable breast cancer.

Authors:  S van Esser; M Hobbelink; J W Van Isselt; W P Th M Mali; I H M Borel Rinkes; R van Hillegersberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-25       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.